HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Garrett L. Walsh Valerie W. Rusch Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Porter, G. A. Articles by Pisters, P. W. T. Search for Related Content PubMed PubMed Citation Articles by Porter, G. A. Articles by Pisters, P. W. T. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2004;127:1366-1372
© 2004 The American Association for Thoracic Surgery

General thoracic surgery

Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: A combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers

^a Dalhousie University, Halifax, Nova Scotia, Canada
^b The University of Texas M. D. Anderson Cancer Center, Houston, Tex,USA
^c Memorial Sloan-Kettering Cancer Center, New York, NY, USA,
^d The University of Singapore, Singapore, Singapore

Received for publication September 23, 2003; revisions received November 13, 2003; revisions received November 20, 2003; accepted for publication November 20, 2003.

^* Address for reprints: Geoffrey A. Porter, MD, Department of Surgery, 7-007 QEII Health Sciences Center, Dalhousie University, 1278 Tower Rd, Halifax, Nova Scotia, Canada B3H 2Y9
Geoff.Porter{at}dal.ca

BACKGROUND: We sought to determine the cost-effectiveness of different treatment strategies for patients with pulmonary metastases from soft tissue sarcoma.

METHODS: We constructed a decision tree to model the outcomes of 4 treatment strategies for patients with pulmonary metastases from soft tissue sarcoma: pulmonary resection, systemic chemotherapy, pulmonary resection and systemic chemotherapy, and no treatment. Data from 1124 patients with pulmonary metastases from soft tissue sarcoma were used to estimate disease-specific survival for pulmonary resection and no treatment. Outcomes of systemic chemotherapy and pulmonary resection and of systemic chemotherapy were estimated by assuming a 12-month improvement in disease-specific survival with chemotherapy; this was done on the basis of the widely held but unproven assumption that chemotherapy provides a survival benefit in patients with metastatic soft tissue sarcoma. Direct costs were examined for a series of patients who underwent protocol-based pulmonary resection or doxorubicin/ifosfamide-based chemotherapy.

RESULTS: The mean cost of pulmonary resection was $20,339 per patient; the mean cost of 6 cycles of chemotherapy was $99,033. Compared with no treatment and assuming a 12-month survival advantage with chemotherapy, the incremental cost-effectiveness ratio was $14,357 per life-year gained for pulmonary resection, $104,210 per life-year gained for systemic chemotherapy, and $51,159 per life-year gained for pulmonary resection and systemic chemotherapy. Compared with pulmonary resection, the incremental cost-effectiveness ratio of pulmonary resection and systemic chemotherapy was $108,036 per life-year gained. Sensitivity analyses showed that certain patient and tumor features, as well as the assumed benefit of chemotherapy, affected cost-effectiveness.

CONCLUSIONS: For patients with pulmonary metastases from soft tissue sarcoma who were surgical candidates, pulmonary resection was the most cost-effective treatment strategy evaluated. Even with favorable assumptions regarding its clinical benefit, systemic chemotherapy alone, compared with no treatment, was not a cost-effective treatment strategy for these patients.

This article has been cited by other articles:

				A. Rehders, S. B. Hosch, P. Scheunemann, N. H. Stoecklein, W. T. Knoefel, and M. Peiper Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma Arch Surg, January 1, 2007; 142(1): 70 - 75. [Abstract] [Full Text] [PDF]